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Abstract 34 
Context: Primary aldosteronism (PA) represents the most frequent form of endocrine hypertension. 35 
Hyperaldosteronism and hypercortisolism both induce excessive left ventricular hypertrophy (LVH) 36 
compared to matched essential hypertensives. In recent studies frequent co-secretion of cortisol and 37 
aldosterone has been reported in PA patients. 38 
Objective: Our aim was to investigate the impact of cortisol co-secretion on left ventricular hypertrophy 39 
in PA patients. We determined 24-h excretion of mineralocorticoids and glucocorticoids by gas 40 
chromatography-mass spectrometry and assessed cardiac remodeling using echocardiography initially and 41 
one year after initiation of treatment for PA. 42 
Patients: We included 73 patients from the Munich center of the German Conn’s registry; 45 with 43 
unilateral aldosterone-producing adenoma and 28 with bilateral adrenal hyperplasia. 44 
Results: At the time of diagnosis, 85% of PA patients showed left ventricular hypertrophy according to 45 
left ventricular mass index (LVMI, median 62.4 g/m
2.
). LVMI correlated positively with total 46 
glucocorticoid excretion (r
2
=0.076, p=0.018) as well as with tetrahydroaldosterone excretion (r
2
=0.070, 47 
p=0.024). Adrenalectomy led to significantly reduced LVMI in aldosterone-producing adenoma (p<0.001) 48 
while mineralocorticoid receptor antagonist therapy in bilateral adrenal hyperplasia patients reduced 49 
LVMI to a lesser degree (p=0.024). In multivariate analysis, the decrease in LVMI was positively 50 
correlated with total glucocorticoid excretion and systolic 24-hour blood pressure, but not with 51 
tetrahydroaldosterone excretion. 52 
Conclusion: Cortisol excess appears to have an additional impact on cardiac remodeling in patients with 53 
PA. Treatment of PA by either adrenalectomy or mineralocorticoid receptor antagonist improves LVMI. 54 
This effect was most pronounced in patients with high total glucocorticoid excretion.  55 
 4 
Introduction 56 
Primary aldosteronism (PA) is the most frequent cause of endocrine hypertension affecting about 57 
5-10 % of patients with elevated blood pressure (1). PA was first described in 1955 by Jerome W. Conn 58 
(2) and characterized in its classical form as hypertension, hypokalemia and alkalosis. Patients with 59 
bilateral adrenal hyperplasia (BAH), the most common subtype, require lifelong treatment with a 60 
mineralocorticoid receptor antagonist (MRA), whereas patients with unilateral aldosterone-producing 61 
adenoma (APA) can be cured by adrenalectomy (ADX). Prolonged exposure to elevated aldosterone 62 
concentrations causes cardiac and renal damage independently of blood pressure (3). These changes may 63 
have adverse impact on clinical outcome. 64 
One of the targets of aldosterone action are cardiomyocytes which express mineralocorticoid 65 
receptors (MR) (4). Indeed, MR activation has been shown to induce myocardial damage (3), including 66 
diffuse myocardial fibrosis, left ventricular hypertrophy (LVH) and left ventricular dilatation (4). In 67 
echocardiographic studies, LVH was more frequent and more progressive in PA patients in comparison to 68 
matched essential hypertensives (5). Likewise, a number of studies have highlighted an increased risk of 69 
stroke, myocardial infarction (MI) and atrial fibrillation in PA patients (6,7). LVH itself is one of the most 70 
important predictors for major cardiac events and mortality and is associated with an increased risk of 71 
arrhythmia, MI and stroke (8). 72 
In a recent study, we identified cortisol co-secretion as a key feature of PA (9) associated with an 73 
adverse metabolic risk phenotype, providing a logical explanation for important comorbidities observed in 74 
patients with primary aldosteronism more aligned with the effects of glucocorticoid rather than 75 
mineralocorticoid excess, such as insulin resistance and type 2 diabetes (10-13), and osteoporosis (14). 76 
Interestingly, pronounced LVH has also been described in patients with Cushing’s syndrome (CS), who 77 
are also afflicted by arterial hypertension, impaired glucose tolerance and serum electrolyte imbalance 78 
(15,16). High cortisol levels in patients with CS are associated with an increased mortality rate due to 79 
cardiovascular complications (17). 80 
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Therefore, we hypothesized that cortisol co-secretion observed in PA might have additional 81 
adverse effects on cardiac function and cardiovascular outcome in PA patients. Thus, our aim was to 82 
investigate the impact of increased cortisol secretion on echocardiographic findings in patients with APA 83 
or BAH.  84 
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Methods 85 
Patients 86 
During 2008 and 2013 we consecutively enrolled 210 patients with primary aldosteronism at the 87 
Munich center of the German Conn’s Registry. In 89 patients a urinary steroid metabolite excretion in  88 
24-h urine was performed and of those 89, 73 patients with either APA (n=45) or BAH (n=28) had a 89 
technically accurate echocardiography examination, which represents the cohort included in this study. 90 
Analysis of urinary steroid metabolite excretion and echocardiography data represented post-hoc analyses. 91 
All patients gave written informed consent, and the protocol of the German Conn’s registry was approved 92 
by the ethics committee of the University of Munich. At each visit, patients underwent standardized 93 
clinical phenotyping including collection of anthropometric data and clinical characteristics such as 94 
duration of hypertension and current medication. 95 
The diagnostic procedures were performed according to the Endocrine Society Practice Guidelines 96 
(18,19). In short, PA was diagnosed by an elevated plasma aldosterone to renin ratio (ARR; cut-off 10.0 97 
ng/mU, sitting position) and an abnormal confirmatory test (e.g. salt loading test, captopril challenge test). 98 
Antihypertensive medication was stopped (n=5) whenever possible prior to testing. Otherwise it was 99 
replaced by alpha 1-adrenergic receptor (doxazosin) or calcium-channel blockers (verapamil) (n=68). 100 
Subtype differentiation between unilateral and bilateral disease was based on adrenal vein sampling 101 
(AVS). In case of APA only patients who underwent ADX were included in the analysis. BAH patients 102 
were treated with MRA. In most patients, spironolactone was used at a dose of 25-50 mg per day. All 103 
patients were re-evaluated one year after treatment in a standardized fashion. 104 
 105 
Laboratory analysis 106 
Blood samples were drawn in a fasting state in sitting position at 8.00 a.m. Plasma aldosterone 107 
concentration was measured using the radioimmunoassay “aldosterone Coat-a-Count” (Biermann DPC). 108 
Active renin concentration was measured by the Liaison chemiluminescence assay (Diasorin). All other 109 
analyses were performed in our central laboratory using standard methods. To determine urinary steroid 110 
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excretion, the patients conducted a 24-hour urine collection. Subsequently, gas chromatography-mass 111 
spectrometry (GC-MS) in selected-ion-monitoring (SIM) analysis mode was performed to determine the 112 
urinary steroid metabolite excretion as described previously (9), allowing the quantification of 40 different 113 
steroid metabolites, including 3α,5β-tetrahydroaldosterone (THAldo), the major mineralocorticoid 114 
metabolite. Total glucocorticoid excretion was calculated as the sum of quantified metabolites of cortisol 115 
and cortisone, comprising tetrahydrocortisol, 5α-tetrahydrocortisol, tetrahydrocortisone, α- and β-cortol, 116 
α- and β-cortolone, 6β-hydroxycortisol, and urinary cortisol and cortisone (9). 117 
 118 
Cardiac ultrasound examination 119 
Comprehensive echocardiographic examination was conducted by experienced sonographers from 120 
the department of internal medicine I (cardiology) from the Ludwig-Maximilians-Universität München. 121 
The sonographers were blinded with regard to diagnosis and clinical details. Commercially available high-122 
quality ultrasound systems were used (GE Healthcare Vivid 7, Philips iE 33). The patients were lying 123 
down in the left lateral decubitus position. Echocardiography included two-dimensional, M-Mode and 124 
Doppler ultrasound recordings. Images were obtained in the parasternal (long and short axis) and apical 125 
views. The left ventricular internal dimension (LVID), interventricular septum (IVS), posterior wall 126 
thickness (PWT) and left atrial dimension in diastole (LAd) were measured via parasternal long axis view. 127 
Echocardiographic parameters were measured according to the recommendation of the American Society 128 
of Echocardiography (20,21). Echocardiography-based left ventricular mass (LVM) estimation is 129 
generally calculated as the difference between epicardium delimited volume and left ventricular chamber 130 
volume multiplied by an estimate of myocardial density (22). The LVM was calculated by the Penn 131 
Convention formula: LVM=1.04 ([LVIDd+PWTd+IVSd]³-[LVIDd]³)-13.6g (23,24). Obesity is 132 
independently associated to LVH (25). Because of higher average values of BMI in our study cohort, 133 
LVH was determined as the left ventricular mass index (LVMI). LVM was indexed by height
2.7 
to obtain 134 
LVMI. By using the LVMI we minimized the interference of obesity in LVM estimation (26). LVH was 135 
prospectively defined as a value of LVMI ≥50 g/m2.7 in males and ≥47g/m2.7 in females (27). Relative wall 136 
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thickness (RWT) was calculated according to the following equation: RWT=(IVSd + PWT)/LVIDd. LVH 137 
was separated in concentric hypertrophy with RWT ≥0.42 and eccentric hypertrophy with RWT <0.42 138 
(21). Normal LVMI values and RWT values ≥0.42 were defined as concentric remodeling (28). 139 
 140 
Statistical analysis 141 
All values are expressed as median and 25th and 75th percentile if not mentioned otherwise. 142 
Within-group changes from baseline to follow-up were calculated by Wilcoxon signed-rank test. 143 
Spearman's Rank Order was used to perform bivariate correlation analysis. Stepwise multiple regression 144 
analysis was used for multivariate analysis. Two-tailed probability values of <5% were considered to be 145 
statistically significant. Statistical analysis was performed using standard statistical software (SPSS 23, 146 
IBM, Chicago, Illinois).  147 
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Results 148 
Patient characteristics  149 
Clinical characteristics of the total cohort of 73 patients with PA are shown in Table 1, the 150 
comparison of APA and BAH subgroups in Table 2. APA and BAH were diagnosed in 45 and 28 151 
patients, respectively. As expected, at diagnosis, patients with APA had higher plasma aldosterone 152 
concentration (p=0.001), higher urinary THAldo concentrations (p=0.001) and lower potassium levels 153 
(p<0.001), and more pronounced renal impairment according to globular filtration rate (GFR; p=0.043). 154 
Total glucocorticoid excretion did not differ between groups (p=0.184). 155 
Patient characteristics one year after initiation of treatment (MRA treatment in BAH, ADX in 156 
APA) are listed in Tables 1+2. Systolic and diastolic blood pressure and serum potassium levels 157 
normalized in both subgroups. As expected, defined daily doses (DDDs) of antihypertensive medication 158 
decreased significantly in the APA group, whereas in the BAH group there was only a trend towards 159 
lower DDDs. BMI remained stable in both groups and both groups had a decline in renal function. 160 
Triglyceride levels increased significantly in both groups, whereas HDL cholesterol levels decreased only 161 
in the BAH group (p=0.006). Pro-BNP, a potential indicator of cardiac preload, improved in both groups. 162 
The decline was not due to optimized treatment for heart failure. In fact, DDDs of ACE inhibitors/ 163 
angiotensin II receptor blockers (1.4 vs. 1.1; p=0.002), beta blockers (0.4 vs. 0.2; p=0.001) and diuretics 164 
(0.4 vs. 0.2; p<0.001) have decreased significantly at follow-up.  165 
 166 
Echocardiographic findings in patients with unilateral aldosteronism and bilateral hyperplasia 167 
Table 3 summarizes echocardiographic geometric characteristics in APA and BAH patients. 168 
LVMI was elevated, the IVS was thickened and the LA was enlarged in both groups at baseline. The 169 
overall prevalence of LVH was 85% before initiation of treatment, compared to 66% at follow-up. There 170 
was a shift from eccentric and concentric hypertrophy towards normal left ventricular geometry (Suppl. 171 
Table 1). As expected, LVMI improved in both APA (p<0.001) and BAH (p=0.024) patients with 172 
treatment (Fig. 1). The reduction of LVMI (∆LVMI) was numerically greater in APA patients with a 173 
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significant decrease of LVIDd (p<0.001), PWTd (p=0.020) and IVSd (p=0.001). In BAH patients only 174 
LVIDd (p=0.001) improved significantly. 175 
 176 
THAldo, total glucocorticoid excretion, urinary sodium excretion and left ventricular structure 177 
As reported previously (9), both THAldo excretion and total glucocorticoid excretion were 178 
increased in PA patients (Table 1). In univariate analysis THAldo (p=0.024), urinary sodium excretion 179 
(p=0.044) and total glucocorticoid excretion (p=0.018) correlated with LVMI at time of diagnosis (Suppl. 180 
Fig. 1+2). In contrast, the relative changes in LVMI in response to treatment (∆LVMI) correlated with 181 
total glucocorticoid excretion (p=0.042), but neither with THAldo (p=0.776) nor with urinary sodium 182 
excretion (p=0.214) (Suppl. Fig. 1+2). Moreover, when arbitrarily dividing PA patients into low and high 183 
steroid secretors, according to whether their THAldo and total glucocorticoid excretion was below or 184 
above the median, high total glucocorticoid excretion, but not THAldo, predicted a reduction in LVMI 185 
(Fig. 2). Similarly, in multivariate analyses, total glucocorticoid excretion and 24-h systolic blood pressure 186 
were strong predictors of left ventricular geometry changes, whereas THAldo did not have a significant 187 
effect in this model (Table 4). One year after treatment we could detect a significant decrease of total 188 
glucocorticoid excretion in APA patients. In accordance with our findings in APA patients with complete 189 
biochemical remission a higher decrease in total glucocorticoid excretion was followed by a more distinct 190 
reduction of LVMI at follow-up (r²=0.138, p=0.023). 191 
 192 
193 
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Discussion 194 
This is the first study to evaluate the impact of glucocorticoid co-secretion on LVH in patients 195 
with PA. PA is characterized by increased aldosterone secretion, but in recent years a relevant cortisol co-196 
secretion has been recognized in several case reports and small case series (29-32). We have recently 197 
reported that increased secretion of glucocorticoids is a major biochemical feature in a large proportion of 198 
patients with PA, whereas clinically overt signs of Cushing’s syndrome are rare (9). We identified cortisol 199 
co-secretion in a substantial percentage of patients with APA and BAH and reported its association with 200 
parameters of the metabolic syndrome, such as BMI, HOMA-IR, and plasma lipids. Moreover, we found 201 
that after unilateral ADX glucocorticoid secretion normalized, followed by postoperative tertiary adrenal 202 
insufficiency in one third of patients. Based on this observation, we wondered whether total glucocorticoid 203 
excretion might also impact on the cardiac phenotype in PA. 204 
Previous echocardiographic evaluations have already demonstrated excess LVM and more 205 
frequent LVH in patients with PA (5,33,34). Our patients with APA and BAH frequently had LVH 206 
according to LVMI; the most common left ventricular adaptation was eccentric hypertrophy. It has been 207 
described before, that high plasma aldosterone concentration results in eccentric changes in LV geometry 208 
(33,35) and that LVM is reduced by either MRA or ADX in patients with PA (36-39). A meta-analysis of 209 
four studies with an average follow-up of four years reported comparable effects for both treatment 210 
strategies (40). In line with this literature, our patients responded to treatment with a significant reduction 211 
in LVMI and an increase in the percentage of normal LV geometry.  212 
At diagnosis, LVMI in the APA group was higher than in the BAH group. At follow-up, our APA 213 
patients showed a trend towards a more distinct reduction in LVMI compared to BAH patients without 214 
reaching statistical significance. Inhibition of MR-mediated aldosterone effects by specific medical 215 
treatment is an explanation for the comparable effects of MRA and ADX in LVM reduction. Our findings 216 
mirror previous studies reporting that the response of LVM reduction in adrenalectomized PA patients 217 
could occur earlier than in PA patients treated with MRA (36). Persistent hyperaldosteronemia with 218 
possible persistence of non-genomic effects of aldosterone has been proposed to potentially explain why 219 
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MRA treatment takes longer to show comparable effects than surgery (41). The results of our study 220 
suppose an impact of cortisol co-secretion on LVH and LV geometry. Total glucocorticoid excretion was 221 
positively correlated with baseline LVMI and ∆LVMI at follow-up. Therefore, patients with higher total 222 
glucocorticoid excretion showed higher decreases in LVMI after one year of treatment. In line with these 223 
findings, the decrease of glucocorticoid excretion correlated with the improvement of LVMI in our APA 224 
patients with biochemical remission. 225 
Chronic cortisol hypersecretion, e. g. in patients with CS, is known to cause amongst others, 226 
truncal obesity, arterial hypertension, impaired glucose tolerance and dyslipidemia (42). However, also a 227 
variety of alterations in cardiac structure and function have been reported, including increased LVM, 228 
increased interventricular septum thickness and concentric hypertrophy or remodeling (15,16,43,44). CS is 229 
known to be associated with elevated cardiovascular morbidity and mortality (45). Cardiac dysfunction 230 
itself represents one of the most important cardiovascular complications affecting mortality. The two 231 
major forms of cardiac dysfunction in CS are cardiac hypertrophy and congestive heart failure (46,47). It 232 
is thought that the main cortisol effects leading to LVH are hypertension, potentiation of noradrenalin and 233 
angiotensin II responsiveness of the cardiomyocytes and cardiomyocyte proliferation and hypertrophy 234 
(48). MRs have similar affinity for aldosterone and cortisol. Glucocorticoid excess impairs conversion of 235 
cortisol to its MR-inactive cortisone by 11-hydroxysteroid dehydrogenase type 2 (11-HSDS2) in 236 
classical aldosterone target issues as the distal nephron, leading to glucocorticoid-mediated 237 
mineralocorticoid effects (49,50). In the cardiomyocytes, 11β-HSDS2 is not expressed at relevant levels. 238 
Therefore, in physiologic circumstances the MR in cardiomyocytes is mostly occupied by cortisol, which 239 
circulates in much higher concentrations than aldosterone. In the event of cardiac tissue damage, cortisol 240 
acts as an MR agonist as shown by Mihailidou et al. in ischemia-reperfusion studies in rat heart 241 
Langendorff preparations (49). This effect can be blocked by spironolactone but not by the 242 
glucocorticoid/progesterone antagonist RU486. However, the abnormalities in LV structure and function 243 
have been reported to ameliorate (44) or even to be reversible upon normalisation of glucocorticoid excess 244 
(51). 245 
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Therefore, treatment with ADX or MRA should both be effective against the MR mediated effects 246 
of glucocorticoid excess on myocardial tissue. To our knowledge no glucocorticoid dependent MR-247 
mediated effects on lipid and glucose metabolism have been reported so far. Therefore, MRA treatment 248 
could be inferior in this regard when increased glucocorticoid secretion in BAH remains unblocked during 249 
MRA treatment in glucocorticoid target organs, such as the endocrine pancreas, abdominal fat tissue and 250 
the liver. In the current study, however, the improvement of glucose metabolism following adrenalectomy 251 
was minimal, but a clinical relevant improvement in glucose homeostasis has been shown previously in 252 
several cohorts (52). 253 
We acknowledge the limitation that steroid metabolite analysis and echocardiography were post 254 
hoc investigations and that our study was neither powered nor planned to examine differences between the 255 
two treatment strategies of PA, ADX and MRA treatment. However, following one year of MRA 256 
treatment, 54% of our BAH patients still had concentric remodeling or concentric hypertrophy as 257 
compared to 42% in APA patients. Therefore, this finding might be explained by ongoing glucocorticoid 258 
effects in BAH patients or inadequate MRA dosage. Unfortunately, we have only limited data for follow-259 
up of urinary glucocorticoid excretion in BAH patients. In addition, one year of follow-up might be too 260 
short to detect full treatment effects of MRA treatment. Therefore, additional studies are required to 261 
address this issue. 262 
It is known that patients with essential hypertension obtain LVM reduction by treatment with 263 
either ACE inhibitor or MRA and that a combination has an additive effect (53). Blood pressure levels and 264 
antihypertensive medication according to DDD´s were reduced in both groups one year after start of 265 
treatment. Although we detected comparable effects on 24-h blood pressure levels, the DDD´s showed 266 
numerically a greater reduction in adrenalectomized APA patients. A contributing factor can be the rather 267 
low dose of spironolactone of an average of 42 mg/d, in accordance with Endocrine Society Practice 268 
Guidelines which can be explained by clinical side effects including gynecomastia preventing further dose 269 
escalation. Similar to previous studies, most of the patients after ADX (58%) still needed 270 
antihypertensives because of residual hypertension (36,54).  271 
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The strengths of our study include the prospective standardized collection of all data and 272 
biomaterial within the context of the German Conn’s registry, the homogeneously characterized study 273 
population, and the subtyping of all patients by adrenal vein sampling. A major limitation of the study is 274 
the very limited follow-up data for urinary steroid excretion (n=5) for BAH patients. Another limitation is 275 
the examination of left ventricular geometry by echocardiography. The main limitation of this technique is 276 
an inappropriate acoustic window, limiting patient inclusion to suitable candidates. Secondly, left 277 
ventricular parameters for estimation of LVM were generated by M-mode measurement. This is less 278 
accurate compared to real time three-dimensional echocardiography or 3D imaging by MRI (55). Thirdly, 279 
echocardiographic examinations in this study were performed by different experienced investigators, 280 
which could have had an influence on wall thicknesses estimation and therefore LVM and LVMI 281 
estimation. However, the investigators were blinded with regard to the underlying cause of disease, which 282 
we consider a strength of the study approach. 283 
 284 
Conclusions 285 
In this study, we investigated the effects of increased glucocorticoid secretion in 73 PA patients 286 
(45 APA, 28 BAH) on cardiac geometry. Our data show that total glucocorticoid excretion is associated 287 
with LVH independent of mineralocorticoid excess. Moreover, high total glucocorticoid excretion, but not 288 
THAldo predicted the ∆LVMI after adrenalectomy in APA patients. In summary, our data suggest a 289 
relevant role of glucocorticoid secretion in PA on LV geometry, pointing out the relevance of cortisol co-290 
secretion in the context of PA. 291 
  292 
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Table 1. Baseline and 1 year follow-up characteristics of all patients with primary aldosteronism.  319 
Data are given as median and 25
th
 and 75
th
 percentile in square brackets. Asterisk indicates significance. 320 
Comparisons were performed by Wilcoxon signed rank test.  321 
Patient characteristics (n=73) n baseline after treatment p 
     
Gender [f/m] 73 28/45 -- n.c. 
Age [years] 73 53 [43; 58] -- n.c. 
Duration of hypertension [months] 73 129 [52; 267] -- n.c. 
Antihypertensive agents [DDD] 73 3.0 [2.0; 4.3] 2.0 [0.1; 3.7] 0.002* 
BMI [kg/m²] 73 27.7 [24.9; 30.9] 27.5 [24.9; 30.3] 0.705 
Aldosterone [ng/l] 73 219.0 [148.0; 346.5] 124.5 [39.8; 198.8] 0.003* 
Plasma renin [mU/l] 73 4.9 [2.2; 13.4] 18.9 [8.9; 44.6] <0.001* 
Serum potassium [mmol/l] 73 3.4 [3.0; 3.7] 4.2 [3.9; 4.5]0 <0.001* 
Serum creatinine [mg/dl] 73 0.8 [0.7; 1.0] 1.0 [0.8; 1.2] <0.001* 
Serum urea [mg/dl] 73 13 [11; 16] 19 [15; 27] <0.001* 
GFR [ml/min/1.73 m²] 73 88.4 [72.3; 100.8] 73.9 [56.3; 85.9] <0.001* 
SBP [mmHg] 73 151 [138; 174] 133 [124; 142] <0.001* 
DBP [mmHg] 73 93 [86; 103] 87 [80; 93] <0.001* 
24h-SBP [mmHg] 57 144 [134; 157] 132 [125; 140] <0.001* 
24h-DBP [mmHg] 57 91 [84; 98] 84 [77; 88] <0.001* 
FPG [mg/dl] 73 102 [93; 113] 99 [91; 107] 0.033* 
HDL-C [mg/dl] 70 56 [47; 70] 49 [40; 62] <0.001* 
LDL-C [mg/dl] 70 124 [92; 151] 126 [100; 142] 0.740 
Triglycerides [mg/dl] 70 105 [72; 134] 114 [86; 178] <0.001* 
Total cholesterol [mg/dl] 70 197 [174; 227] 200 [174; 219] 0.995 
Diabetes mellitus [n] 73 8 (11%) 8 (11%) n.c. 
Total glucocorticoid excretion [µg/24h]; 
median of healthy controls: 8262 
[6380; 11044] 
73 
 
11807 
[8270; 15266 
-- n.c. 
44 
 
12772  
[9000; 16131]§ 
9458  
[5578; 13460]§ 
<0.001* 
 
Tetrahydroaldosterone excretion 
[µg/24h];  
median of healthy controls: 30 [22; 44] 
73 82 [52; 128] -- n.c. 
44 88 [57; 131]§ 21 [14; 39]§ <0.001* 
Abbreviations: FPG: fasting plasma glucose; DDD: defined daily dose; SBP: systolic blood pressure; 322 
DBP: diastolic blood pressure; §: dataset of 44 patients with complete follow-up data, n.c.: not calculated.323 
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Table 2. Baseline and 1 year follow-up characteristics of patients with primary aldosteronism according to subtype. 324 
Data are given as median and 25
th
 and 75
th
 percentile in square brackets. Asterisk indicates significance. Comparisons were performed by 325 
Wilcoxon signed-rank-test and by McNemar-test. Differences between baseline values of both group were marked with # for p<0.05 and ## for 326 
p<0.0001. 327 
Patient characteristics 
Aldosterone producing adenoma 
(n=45) 
p 
 
Bilateral adrenal hyperplasia 
(n=28) 
p 
 
Time of assessment baseline after ADX  baseline after MRA  
Age [years] 54 [46; 60] -- n.c. 49 [41; 58] -- n.c. 
Sex [f/m] 17/28 -- n.c. 11/17 -- n.c. 
Duration of 
hypertension [months] 
130 [55; 250] 
 
-- 
 n.c. 
130 [35; 283] 
 
-- 
 n.c. 
BMI [kg/m²] 27.7 [24.9; 32.1] 28.1 [25.2; 30.3] 0.803 27.6 [25.0; 30.7] 27.1 [24.3; 30.4] 0.323 
Aldosterone [ng/l] 242.0 [181.6; 427.9] 53.0 [35.0; 129.5] <0.001* 159.5 [110.5;247.5]# 216.0 [160.0;388.6] <0.001* 
Plasma renin [mU/l] 5.5 [2.1; 12.1] 17.0 [9.1 45.1] <0.001* 4.7 [2.5; 15.8] 19.9 [7.7; 45.0] <0.001* 
Serum potassium 
[mmol/l] 
3.2 [2.8; 3.5] 
 
4.2 [3.9; 4.5] 
 
<0.001* 
 
3.6 [3.2; 3.8]## 
 
4.2 [3.9; 4.5] 
 
<0.001* 
 
Serum creatinine 
[mg/dl] 
0.8 [0.8; 1.0] 
 
1.1 [0.9; 1.3] 
 
<0.001* 0.8 [0.7; 0.9] 
 
0.8 [0.7; 1.1] 
 
0.016* 
 
Serum urea [mg/dl] 13 [11; 16] 22 [16; 29] <0.001* 13 [10; 17] 16 [13; 24] 0.003* 
GFR [ml/min/1.73 m²] 79.4 [69.9; 99.6] 68.8 [54.5; 77.8] <0.001* 93.9 [84.1; 104.3]# 81.3 [71.5; 105.9] 0.031* 
SBP [mmHg] 152 [139; 172] 133 [126; 144] <0.001* 146 [134; 175] 132 [123; 137] 0.005* 
DBP [mmHg] 93 [87; 105] 87 [80; 94] 0.001* 92 [86; 101] 88 [79; 93] 0.106 
24-SBP [mmHg] † 149 [139; 157] 132 [125; 140] <0.001* 144 [131; 155] 132 [123; 139] 0.032* 
24-DBP [mmHg] † 91 [86; 99] 83 [77; 87] <0.001* 91 [83; 98] 84 [76; 88] 0.007* 
FPG [mg/dl] 102 [94; 112] 99 [91; 106] 0.043* 101 [91; 119] 100 [90; 112] 0.692 
Diabetes mellitus [n] 5 (11%) 5 (11%) n.c. 3 (11%) 3 (11%) n.c. 
HDL-C [mg/dl] † 54 [47; 69] 49 [42; 64] 0.076 56 [47; 72] 51 [39; 62] 0.006* 
LDL-C [mg/dl] † 133 [92; 151] 126 [97; 145] 0.861 123 [92; 152] 126 [101; 142] 0.409 
Triglycerides [mg/dl] † 103 [66; 134] 113 [79; 169] 0.001* 107 [80; 135] 117 [95; 190] 0.005* 
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Total cholesterol 
[mg/dl] † 
203 [174; 231] 
 
200 [170; 221] 
 
0.480 192 [173; 221] 
 
197 [175; 219] 
 
0.402 
 
Antihypertensive 
agents [DDD] 
3.5 [2.0; 4.7] 
 
1.5 [.0; 3.2] 
 
<0.001* 3.0 [1.6; 3.5] 
 
2.7 [1.0; 4.6] 
 
0.848 
 
Tetrahydroaldosterone 
excretion [µg/24h] 
95 [63; 140]  n.c. 55 [40; 97]#  n.c. 
95 [62; 147]§ 18 [13; 31]§ <0.001* 54 [39; 77]§§ 60 [38; 70]§§ n.c. 
Total glucocorticoid 
excretion [µg/24h] 
 
12980 [9200; 15266]  n.c. 9908 [6328; 16109]  n.c. 
12563  
[9015; 15516]§ 
9304  
[5522; 11300]§ 
<0.001* 19943  
[8573; 24897]§§ 
17073 
[6603; 17581]§§ 
n.c. 
 
Total sodium excretion 
[mmol/24h] 
204 [136; 238] 
 
164 [131; 257] 
 
0.200 186 [150; 224] 
 
196 [115; 240] 
 
0.713 
 
Pro-BNP[pg/ml] 117 [52; 297] 68 [32; 124] <0.001* 96 [61; 167] 65 [41; 117] 0.023* 
Abbreviations: ADX: adrenalectomy; MRA: mineralocorticoid receptor antagonist treatment; FPG: fasting plasma glucose; DDD: defined daily 328 
dose; SBP: systolic blood pressure; DBP: diastolic blood pressure; §: dataset of 44 patients with complete follow-up data, §§: dataset of 5 patients 329 
with complete follow-up data, n.c.: not calculated, †: Due to incomplete data the calculations for 24-SBP and 24-DBP (APA n=35, BAH n=22), 330 
and HDL-C, LDL-C, Triglycerides, Total cholesterol (APA n=43, BAH n=27) were performed with a reduced number of patients as listed in 331 
brackets.332 
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Table 3. Echocardiographic characteristics of patients with primary aldosteronism according to subtype. 333 
Data are given as median and 25th and 75th percentile in square brackets. Asterisk indicates significance. Comparisons were performed by 334 
Wilcoxon signed-rank-test. 335 
Left ventricular 
parameters 
Aldosterone producing adenoma 
(n=45) 
p 
 
Bilateral adrenal hyperplasia 
(n=28) 
p 
 
Time of 
assessment 
baseline 
 
after ADX 
 
 
baseline 
 
after MRA 
 
 
 
LVMI [g/m
2.7
] 64.6 [54.7; 71.4] 56.5 [42.7; 63.6] <0.001* 57.8 [50.3; 70.1] 53.5 [42.1; 65.2] 0.024* 
∆LVMI [g/m2.7]  8.0 [1.5;18.3] n.c.  6.4 [-2.0; 14.4] n.c. 
LVIDd [mm] 52 [49; 56] 50 [47; 53] <0.001* 52 [47; 55] 49 [44; 53] 0.001* 
LVIDs [mm] 31 [29; 36] 30 [27; 33] 0.128 31 [28; 34] 29 [26; 34] 0.083 
PWTd [mm] 10 [9; 12] 10 [9; 11] 0.020* 10 [8; 11] 10 [9; 12] 0.319 
IVSd [mm] 12 [11; 13] 11 [10; 13] 0.001* 12 [10; 13] 12 [10; 13] 0.072 
RWTd [cm] 0.40 [0.35; 0.47] 0.40 [0.36; 0.46] 0.775 0.39 [0.33; 0.44] 0.43 [0.38; 0.50] 0.014* 
LAd [mm] 42 [38; 46] 39 [36; 43] <0.001* 42 [36; 47] 41 [33; 46] 0.090 
Abbreviations: ADX: adrenalectomy; MRA: mineralocorticoid receptor antagonist treatment; LVMI: left ventricular mass indexed for height to the 336 
2.7 power; ∆LVMI: reduction of left ventricular mass indexed for height to the 2.7 power after treatment; LVM: left ventricular mass, LVIDd: left 337 
ventricular internal dimension in diastole; LVIDs: left ventricular internal dimension in systole; PWTd: posterior wall thickness in diastole; IVSd: 338 
interventricular septum thickness in diastole; RWTd: relative wall thickness in diastole; LAd: left atrial internal dimension in diastole, n.c.: not 339 
calculated. 340 
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Table 4. Uni- and multivariate analyses of the associations with echocardiographic parameters in all 341 
patients with primary aldosteronism. 342 
Data are given as p values. Asterisk indicates significance. Correlation analysis was performed using 343 
Spearman's Rank-Order test and stepwise multiple regression analysis. 344 
 
THAldo TGE 24h-SBP THAldo, TGE, 24h-
SBP 
Left ventricular 
parameters 
 
Univariate, p Univariate, p Univariate, p Multivariate 
LVMI [g/m
2.7
] 0.024* 0.018* <0.001* 24h-SBP* 
∆LVMI [g/m2.7] 0.776 0.042* 0.008* 24h-SBP* 
LVIDd [mm] 0.531 0.003* 0.052 TGE* 
IVSd [mm] 0.119 0.105 0.003* 24h-SBP* 
PWTd [mm] 0.277 0.008* 0.003* TGE*, 24h-SBP* 
LAd [mm] 0.523 0.026* 0.008* n.s. 
Abbreviations: LVMI: left ventricular mass indexed for height to the 2.7 power; ∆LVMI: reduction of left 345 
ventricular mass indexed for height to the 2.7 power after treatment; LVM: left ventricular mass,  346 
LVIDd: left ventricular internal dimension in diastole; PWTd: posterior wall thickness in diastole; 347 
IVSd: interventricular septum thickness in diastole; LAd: left atrial internal dimension in diastole; 348 
24h-SBP: 24-hour systolic blood pressure, THAldo: tetrahydroaldosterone; TGE: total glucocorticoid 349 
excretion; n.s.: no significant results. 350 
  351 
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Supplementary Table 1. Changes in left ventricular geometry of all patients with primary 352 
aldosteronism after one year of treatment. 353 
Left ventricular geometry 
Aldosterone producing adenoma 
(n=45) 
Bilateral adrenal hyperplasia 
(n=28) 
Time of assessment baseline after ADX baseline after MRA 
Normal (%) 13 22 18 25 
Concentric Remodeling (%) 0 11 0 11 
Eccentric Hypertrophy (%) 51 36 43 21 
Concentric Hypertrophy (%) 36 31 39 43 
Abbreviations: APA: unilateral disease; BAH: bilateral disease; ADX: adrenalectomy;  354 
MRA: mineralocorticoid receptor antagonist treatment. 355 
  356 
 22 
Figure Legends 357 
 358 
Figure 1: LVMI at baseline and after treatment in BAH and APA patients treated with either MRA 359 
or ADX. 360 
Median and 95 per cent confidence interval of LVMI are shown before (white bar) and after treatment 361 
(checkered bar). Asterisk indicates significance. 362 
Abbreviations: APA: unilateral disease; BAH: bilateral disease; LVMI: left ventricular mass indexed for 363 
height to the 2.7 power. 364 
Figure 2: Reduction of LVMI following specific treatment according to baseline total glucocorticoid 365 
excretion and THAldo levels. 366 
Median and 95 per cent confidence interval of baseline glucocorticoid and THAldo excretion of PA 367 
patients with low and high total glucocorticoid (8390 µg/24h; 15266 µg/24h) or THAldo (52 µg/24h; 121 368 
µg/24h) excretion are shown. Asterisk indicates significance.  369 
Abbreviations: APA: unilateral disease; BAH: bilateral disease, LVMI: left ventricular mass indexed for 370 
height to the 2.7 power; TGE: total glucocorticoid excretion; THAldo: tetrahydroaldosterone. 371 
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Figure 2:  387 
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Supplementary Figure Legends 420 
 421 
Supplementary Figure 1: Correlation of total glucocorticoid excretion with left ventricular mass indexed 422 
for height to the 2.7 power at baseline in patients with primary aldosteronism. 423 
Supplementary Figure 2: Correlation of tetrahydroaldosterone excretion with left ventricular mass 424 
indexed for height to the 2.7 power at baseline in patients with primary aldosteronism. 425 
Supplementary Figure 3: Correlation of baseline glucocorticoid excretion with reduction of left 426 
ventricular mass indexed for height to the 2.7 power in patients with primary aldosteronism. 427 
Supplementary Figure 4: Correlation of baseline tetrahydroaldosterone excretion with reduction of left 428 
ventricular mass indexed for height to the 2.7 power in patients with primary aldosteronism. 429 
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Supplementary Figure 1: 445 
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Supplementary Figure 2:  458 
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Supplementary Figure 3: 473 
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Supplementary Figure 4: 487 
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